Our business is built around the Novo Nordisk Way, our commitment to be a sustainable business and our clear patient-centric purpose: driving change to defeat serious chronic diseases. Our key contribution is to discover and develop innovative medicines and make them accessible to patients throughout the world.

We will strengthen our leadership in diabetes and obesity, secure a leading position within rare disease and establish ourselves in cardiovascular disease (CVD). We also aim to build a presence in emerging therapy areas, such as metabolic dysfunction-associated steatohepatitis (MASH), chronic kidney disease (CKD) and Alzheimer’s disease (AD), and to move toward disease-modifying and curative therapies.

Reduce CO2 equivalent emissions across the value chain

  • Achieve net zero CO2 equivalent emissions by 2045
  • Set an absolute, near-team scope 3 reduction target by the end of 2024
  • Achieve zero CO2 equivalent emissions from operations and transportation by 2030.

Reduce the plastic footprint from our products

  • Replace plastic in our products with fossil-free alternatives
  • Reduce plastic waste that ends up in landfill. Collect 25% of the injection pens in Denmark and achieve an 85% recycling rate by the end of 2024.

Reach more vulnerable patients

  • Secure access to affordable insulin for patients in all countries where we operate
  • Reach 100,000 vulnerable children and adolescents living with type 1 diabetes by 2030
  • Secure thermal stability of short- and intermediate-acting human insulin products
  • Secure local production of insulin in the African continent with the target to produce more than 60 million vials by 2026.

Reach more people with prevention

  • Promote prevention efforts and address barriers to health for vulnerable populations and children
  • Directly impact at least 10 million children through programmatic activities by 2026.

Ensure an inclusive and diverse organisation

  • Sustain progress on the state of inclusion in Novo Nordisk
  • Mitigate bias in pay processes and decisions
  • Achieve a balanced gender representation across all managerial levels and a minimum of 45% women and 45% men in senior leadership positions by the end of 2025.

Improve employee’s safety, mental and physical well-being

  • Ensure that all employees get the opportunity to bond with their child though parental leave.

Embed the Novo Nordisk Way in our company behaviours

  • Adhere to the Novo Nordisk Way
  • Train all Novo Nordisk employees annually in ethics and compliance
  • Complete 45 business ethics reviews in 2024.